Akebia Therapeutics Inc
NASDAQ:AKBA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Akebia Therapeutics Inc
NASDAQ:AKBA
|
US |
|
G
|
General Dynamics Corp
XHAM:GDX
|
US |
|
Puradelta Lestari Tbk PT
OTC:PTPLF
|
ID |
|
F
|
Fraport AG Frankfurt Airport Services Worldwide
XHAM:FRA
|
DE |
|
Unicharm Corp
OTC:UNCHF
|
JP |
|
Porr AG
F:ABS2
|
AT |
|
O
|
Old Second Bancorp Inc
XBER:OSB
|
US |
|
G
|
Gilead Sciences Inc
DUS:GIS
|
US |
Wall St Price Targets
AKBA Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AKBA is 4.28 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AKBA's stock price target?
Price Target
4.28
USD
According to Wall Street analysts, the average 1-year price target for AKBA is 4.28 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-1%
The compound annual growth rate for Gross Profit over the next 3 years is -1%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
34%
The compound annual growth rate for Operating Income over the next 8 years is 34%.
